Jing Tang*1, Xu Yong Li†1, Jing Bo Liang‡, De Wu§, Li Peng¶, Xiaobing Li¶
Oncology Research, Vol.27, No.6, pp. 635-641, 2019, DOI:10.3727/096504018X15288447760357
Abstract Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced
gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell
lung cancer (NSCLC). Since the combination of chemotherapy and an antiangiogenic agent has been shown
to be a feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical activity. With this in mind, we investigated the efficiency of apatinib in combination
with pemetrexed or docetaxel in advanced NSCLC. We treated a… More >
Login
Register
